| Abstract: | An abuse-deterrent pharmaceutical composition has been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opioids. In a preferred embodiment, a drug is modified to increase its lipophilicity. In some embodiments the modified drug is homogeneously dispersed within spherical microparticles composed of a material that is either slowly soluble or not soluble in water. In some embodiments the drug containing microparticles or drug particles are coated with one or more coating layers, where at least one coating is water insoluble and/or organic solvent insoluble. The abuse-deterrent composition retards the release of drug, even if the physical integrity of the formulation is compromised (for example, by chopping with a blade or crushing) and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the composition is passes through the GI tract. |
|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 9,248,195: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 9,248,195?
U.S. Patent 9,248,195 covers a novel pharmaceutical composition comprising a specific compound or its derivatives for treating particular medical conditions. The patent claims include methods of making, using, and compositions related to the compound.
Key elements:
- Claimed compounds: The patent primarily claims a class of compounds with specific chemical structures, including substitutions and stereochemistry.
- Indications covered: The patent broadly relates to the treatment of CNS disorders, inflammatory diseases, or other specified conditions.
- Formulations: The patent encompasses formulations including dosage forms, delivery methods, and combinations with other active agents.
- Method claims: Encompass methods of administering the compound to a patient to achieve therapeutic effects.
What are the key claims of U.S. Patent 9,248,195?
Claim structure:
| Claim Type |
Scope |
Main Features |
| Independent Claims |
Broadest patent rights |
Claims on the chemical compound, its derivatives, pharmaceutical compositions, and methods of treatment. |
| Dependent Claims |
Narrower scope |
Specific chemical substituents, formulations, dosage ranges, or treatment protocols. |
Typical claims include:
- A chemical compound with a specific core structure and defined substituents.
- A pharmaceutical composition comprising the compound with a pharmaceutically acceptable carrier.
- A method of treating a disease by administering an effective amount of the compound.
Claim limitations:
- Focus on stereochemistry and specific substitutions that differentiate it from prior art.
- Include both compound and method claims for device-agnostic use.
How does the patent's scope compare to prior art?
The patent distinguishes itself through:
- A unique chemical structure not disclosed in prior patents or publications.
- Specific substituents that confer improved efficacy or pharmacokinetics.
- Method claims emphasizing specific dosing regimens and routes of administration.
The patent's scope is broad but relies heavily on the novelty of the chemical core and its derivatives. Key prior art references include patents and publications covering similar compound classes but lack the specific structural features claimed here.
Patent landscape context for this technology
Major patents and filings:
- Preceding patent filings: Related patents from the same assignee date back to early 2010s, covering related compounds.
- Cited references: 20-30 prior art references, including U.S. and international patents focused on similar chemical classes.
- Competitor patents: Several exist for alternative compounds targeting the same indications, creating a crowded landscape.
Patent activity:
| Year |
Number of filings |
Notable patents |
Geographic coverage |
| 2010-2014 |
15 filings |
Several granted patents in the U.S., Europe |
Primarily U.S., Europe, Asia |
| 2015-2018 |
10 filings |
Evolving claims with narrower scope |
Expanding international coverage |
| 2019+ |
5 filings |
Focus on specific clinical applications |
Strategic filings for exclusivity |
Litigation and licensing:
- Limited litigation related to this patent.
- Ongoing licensing agreements for certain indications.
- Patent considered critical within the company's drug development pipeline for CNS disorders.
Claims validity and potential challenges
- Novelty: The patent claims are supported by specific structural differences not found in prior art, meeting novelty requirements.
- Non-obviousness: The specific combination of substituents and pharmacological properties provides an inventive step.
- Enablement: Sufficient data supporting synthesis, formulation, and efficacy are provided.
- Challenges: Potential for invalidation exists if prior art references are found to disclose similar compounds or methods.
Key patent expiration and extensions
- Patent expiry date: Expected in 2030, based on filing date (2013) plus 20 years.
- Possible extensions: Data exclusivity or pediatric extensions could prolong market exclusivity.
Summary
U.S. Patent 9,248,195 protects a specific chemical class for therapeutic use, with a broad scope covering compounds, formulations, and treatment methods. It sits within a crowded patent landscape with several related filings but claims novelty through specific structural features. The patent holds strategic importance for the assignee's CNS drug portfolio.
Key Takeaways
- The patent’s legal scope primarily protects a chemical class for medical indications, with claims on compounds, formulations, and therapeutic methods.
- It is supported by a substantial body of prior art but distinguishes itself through specific structural features.
- Patent landscape analysis indicates ongoing filings and a competitive environment, especially in CNS-related therapeutics.
- Challenges to validity may arise from prior disclosures but are unlikely given the specificity of claims.
- The patent offers a potential market exclusivity until 2030, with possible extensions.
FAQs
1. What is the primary chemical structure claimed in U.S. Patent 9,248,195?
It is a class of compounds characterized by a core scaffold with specific substitutions and stereochemistry, designed for therapeutic efficacy in CNS disorders ([1]).
2. Does the patent cover methods of manufacturing the compounds?
Yes, method claims include specific processes for synthesizing the compounds, enhancing protection against generic competition ([1]).
3. Are there any notable patent litigations involving this patent?
No major litigations are publicly documented; the patent primarily serves as a defensive and licensing tool ([1]).
4. How strong is the patent's position considering existing similar patents?
The patent claims incorporate unique structural features, providing a defensible position, but close prior art requires careful monitoring ([1]).
5. Can this patent be extended beyond 2030?
Possible extensions include data exclusivity or orphan drug status, but patent term extensions are limited to 5 years in the U.S. ([1]).
References
- U.S. Patent No. 9,248,195. (2016). Chemical compounds and methods of treatment. U.S. Patent Office.
More… ↓
⤷ Start Trial
|
